June 2026 Research Update

This month added a clearer picture that CDKL5 loss may shift the timing of early brain development rather than causing uniform changes everywhere. In a mouse study of the visual cortex, signs of perineuronal nets (supportive structures around certain brain cells) appeared stronger earlier and differed by subregion, suggesting that some areas may mature too soon while others develop differently. This matters because these structures are linked to how brain circuits stabilize during early-life learning periods. [1]

By about 2 weeks of age in mice (P15), the CDKL5-null group had higher overall staining intensity for these nets across several visual cortex subregions, which the authors interpreted as earlier-than-usual net development. By about 1 month (P30), the pattern was more mixed: one subregion (V1M) showed fewer nets overall, while another (V1B) showed more of the strongest-intensity nets compared with typical mice. Taken together, the results point to region-by-region changes in how inhibitory circuits may be settling into place during a sensitive developmental window. [1]

For families, this is early-stage laboratory research that does not predict a specific symptom or outcome for an individual child. What it adds right now is a more detailed clue about biology: CDKL5 loss may change when and where brain circuits become more "locked in" during early development, at least in mice. What remains uncertain is how these mouse visual-cortex changes relate to seizures, vision, development, or treatment response in people with CDKL5 deficiency disorder. [1]

This month included a reminder that CDKL5 deficiency disorder can be hard to recognize early because clinical signs and brain imaging can resemble other conditions. In one infant, seizures started very early and evolved into difficult-to-control epilepsy with profound developmental delay, while early MRI findings looked similar to a mitochondrial disorder. The report highlights that genetic testing may clarify the diagnosis even when other tests point in different directions. [2]

The child had epileptic spasms in early infancy and later developed pharmacoresistant epilepsy with severe developmental impairment. Genetic testing found a CDKL5 change (c.68C>A; p.Ala23Asp) labeled as a variant of uncertain significance, meaning it was not definitively proven to be disease-causing in this report. The authors noted that parental testing was ongoing, reflecting how sometimes more family data is needed to interpret a result. [2]

For patients and caregivers, this single case mainly adds context about the diagnostic journey rather than providing a broadly applicable new finding. It helps clarify that MRI changes and seizure patterns alone may not cleanly separate CDKL5 deficiency disorder from other neurologic conditions in early life, and that genetic findings can sometimes be difficult to interpret when a variant is labeled uncertain. What remains uncertain from this report is whether the specific CDKL5 variant described will ultimately be confirmed as disease-causing, and how often similar MRI patterns occur in CDKL5 deficiency disorder. [2]